Oric Pharmaceuticals, Inc. ORIC Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $109.82M-3.7% | $114.07M+33.9% | $85.17M+38.1% | $61.68M+8.5% | ||
| $33.19M+15.1% | $28.82M+12.6% | $25.61M+2.1% | $25.09M+14.0% | ||
| $143M+0.1% | $142.9M+29.0% | $110.78M+20.7% | $91.77M+16.4% | ||
| -$143M-0.1% | -$142.9M-29.0% | -$110.78M-20.7% | -$91.77M-16.4% | ||
| $13.54M-10.0% | $15.05M+49.2% | $10.08M+281% | $2.65M+1,596% | ||
| -$129.47M-1.3% | -$127.85M-27.0% | -$100.7M-13.0% | -$89.12M-13.2% | ||
| -$1.49+18.1% | -$1.82+7.6% | -$1.97+12.4% | -$2.25-8.7% | ||
| -$141.78M0.0% | -$141.79M-29.2% | -$109.75M-20.9% | -$90.8M-16.5% | ||
| -$143M-0.1% | -$142.9M-29.0% | -$110.78M-20.7% | -$91.77M-16.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Oric Pharmaceuticals, Inc. profitable?
- Oric Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $135.2M over the trailing twelve months.
- What is Oric Pharmaceuticals, Inc.'s earnings per share?
- Oric Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.
- Where does Oric Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.